Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation.
The development of technology to measure antigen presentation in the secondary lymphoid system has provided the opportunity of analysing components of the host antitumour immune response that have, until now, been unavailable for study. In particular, this technology has enabled us to evaluate threshold levels of tumour antigen required for cross-presentation in draining lymph nodes, the duration of this antigen presentation and processes that regulate tumour antigen presentation. Thus, we have been able to dissect out the relationship between antigen presentation and the resultant development of effector function in class I-restricted T cells, as well as the role of regulatory CD4 cells. We have also used this technology to evaluate the effects of antitumour therapy on local antigen cross-presentation.
Robinson
B W
BW
University Department of Medicine, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia. bwsrobin@cyllene.uwa.edu.au
Lake
R A
RA
Nelson
D J
DJ
Scott
B A
BA
Marzo
A L
AL
D019264:Adoptive Transfer; D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D002455:Cell Division / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D000939:Epitopes / Q000276:immunology; D005452:Fluoresceins; D006801:Humans; D008208:Lymphatic System / Q000166:cytology / Q000276:immunology*; D051379:Mice; D013388:Succinimides; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology; D013997:Time Factors; D014018:Tissue Distribution / Q000276:immunology
C087165:5-(6)-carboxyfluorescein diacetate succinimidyl ester; D000951:Antigens, Neoplasm; D000939:Epitopes; D005452:Fluoresceins; D013388:Succinimides